Inhibition of PCAF histone acetyltransferase and cytotoxic effect of N-acylanthranilic acids

Archives of Pharmacal Research

Volumn 35, Issue 8, 2012, Pages 1379-1386

  Park, Woong Jae ^a   Ma, Eunsook ^a  

^a Catholic University of Daegu   (South Korea)

Author keywords

Cytotoxicity; Histone acetyltransferase (HAT); N Acylanthranilic acid; P300 CBP associated factor (PCAF)

Indexed keywords

ANACARDIC ACID; ANTHRANILIC ACID DERIVATIVE; ANTINEOPLASTIC AGENT; HISTONE ACETYLTRANSFERASE PCAF; N ACYL 5 HYDROXYANTHRANILIC ACID; N ACYLANTHRANILIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; ENZYME ASSAY; ENZYME INHIBITION; HELA CELL; HUMAN; HUMAN CELL;

ANACARDIC ACIDS; ANTINEOPLASTIC AGENTS; CELL LINE; CELL LINE, TUMOR; ENZYME INHIBITORS; HUMANS; NEOPLASMS; ORTHO-AMINOBENZOATES; P300-CBP TRANSCRIPTION FACTORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84868098451     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-012-0807-2     Document Type: Article

References (29)

1. Biel, M., Wascholowski, V., and Giannis, A., Epigenetics-an epicenter of gene regulation: histones and histone-modifying enzymes. Angew. Chem. Int. Ed. Engl., 44, 3186-3216 (2005). (Pubitemid 40778337)
2. Balasubramanyam, K., Swaminathan, V., Ranganathan, A., and Kundu, T. K., Small molecule modulators of histone acetyltransferase p300. J. Biol. Chem., 278, 19134-19140 (2003). (Pubitemid 36799302)
3. Balasubramanyam, K., Varier, R. A., Altaf, M., Swaminathan, V., Siddappa, N. B., Ranga, U., and Kundu, T. K., Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone protein and histone acetyltransferase-dependent chromatin. J. Biol. Chem., 279, 51163-51171 (2004). (Pubitemid 40017859)
4. Carrozza, M. J., Utley, R. T., Workman, J. L., and Cote, J., The diverse functions of histone acetyl transferase complexes. Trends Genet., 19, 321-329 (2003). (Pubitemid 36694615)
5. Cocco, M. T, Congiu, C., Onnis, V., and Lilliu, V., Synthesis of new N-(2-trifluoromethyl)pyridine-4-yl)anthranilic acid derivatives and their evaluation as anticancer agents. Bioorg. Med. Chem. Lett., 14, 5787-5791 (2004). (Pubitemid 39421519)
6. Congiu, C., Cocco, M. T., Lilliu, V., and Onnis, V., New potential anticancer agents based on the anthranilic acid scaffold. Synthesis and evaluation of biological activity. J. Med. Chem., 48, 8245-8252 (2005). (Pubitemid 43032533)
7. Conte, M., Alvarez, R., Nebbioso, A., Carafa, V., Altucci, L., and de Lera, A. R., Synthesis of benzamide related to anacardic acid and their histone acetyltransferase (HAT) inhibiting activities. ChemMedChem, 3, 1435-1442 (2008).
8. Davis, C. D. and Ross, S. A., Dietary components impact histone modifications and cancer risk. Nutr. Rev., 65, 88-94 (2007). (Pubitemid 351804383)
9. Dekker, F. J. and Haisma, H. J., Histone acetyl transferases as emerging drug targets. Drug Discov. Today, 14, 942-948 (2009a).
10. Dekker, F. J., Ghizzoni, M., van der Meer, N., Wisastra, R., and Haisma, H. J., Inhibition of the PCAF histone acetyl-transferase and cell proliferation by isothiazolones. Bioorg. Med. Chem., 17, 460-466 (2009b).
11. Feinberg, A. P. and Vogelstein, B., Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature, 301, 89-92 (1983). (Pubitemid 13154475)
12. Ghizzoni, M., Boltjes, A., de Graaf, C, Haisma, H. J., and Dekker, F. J., Improved inhibition of the histone acetyl transferase PCAF by an anacardic acid derivative. Bioorg. Med. Chem., 18, 5826-5834 (2010).
13. Green, I. R., Tocoli, F. E., Lee, S. H., Nihei, K., and Kubo, L., Molecular design of anti-MRSA agents based on the anacardic acid scaffold. Bioorg. Med. Chem., 15, 6236 (2007).
14. Hake, S. B., Xiao, A., and Allis, C. D., Linking the epigenetic 'language' of covalent histone modification to cancer. Br. J. Cancer, 90, 761-769 (2004). (Pubitemid 38406583)
15. Hird, N. W. and Milner, P. H., Synthetic and β-lactamase inhibition of anacardic acids and their analogues. Bioorg. Med. Chem. Lett., 4, 1423-1426 (1994).
16. Inche, A. G. and La Thangue, N. B., Chromatin control and cancer-drug discovery: realizing the promise. Drug Discov. Today, 11, 97-109 (2006). (Pubitemid 43375960)
17. Lau, O. D., Kundu, T. K., and Soccio, R. E., HATs off: selective synthetic inhibitors of the histone acetyltransferase p300 and PCAF. Mol. Cell, 5, 589-595 (2000).
18. Mai, A., Rotili, D., Tarantino, D., Ornaghi, P., Tosi, F., Vicidomini, C., Sbaedella, G., Nebbioso, A., Miceli, M., Altucci, L., and Filetici, P., Small-molecular inhibitors of histone acetyltransferase activity: Identification and biological properties. J. Med. Chem., 49, 6897-6907 (2006). (Pubitemid 44749755)
19. Muraoka, M., Konishi, M., Kikuchi-Yanoshita, R., Tanaka, K., Shitara, N., Chong, J. M., Iwama, T., and Miyaki, M., p300 gene alteration in cololectal and gastric carcinoma. Oncogene, 12, 1565-1569 (1996). (Pubitemid 26132043)
20. Nakao, M., Epigenetics: interaction of DNA methylation and chromatin. Gene, 278, 25-31 (2001). (Pubitemid 33055776)
21. Pruss, D., Hayes, J. J., and Wolffe, A. P., Nucleosomeal anatomy-where are the histones? Bioessays, 17, 161-170 (1995).
22. Sbardella, G., Castellano, S., Vicidomini, C., Rotili, D., Nebbioso, A., Miceli, M., Aitucci, L., and Mai, A., Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyl transferases. Bioorg. Med. Chem. Lett., 18, 2788-2792 (2008). (Pubitemid 351608893)
23. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bodesh, H., Kenny, S., and Boyd, M. R., New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst., 82, 1107-1112 (1990). (Pubitemid 20213250)
24. Souto, J. A., Conte, M., Alvarez, R., Nebbioso, A., Carafa, V., Aitucci, L., and de Lera, A. R., Synthesis of benzamides related to anacardic acid and their histone acetyl-transferase (HAT) inhibitory activities. ChemMedChem, 3, 1435-1442 (2008).
25. Stimson, L., Rowlands, M. G., Newbatt, Y. M., Smith, N. F., Raynaud, F. I., Rogers, P., Bavetsias, V., Gorsuch, S., Jarman, M., Bannister, A., Kouzarides, T., McDonald, E., Workman, P., and Aherne, G. W., Isothiazolones as inhibitors of PCAF and p300 histone acetyl-transferase activity. Mol. Cancer Ther., 4, 1521-1532 (2005). (Pubitemid 41556434)
26. Trievel, R. C., Li, F. Y., and Marmorstein, R., Appliaction of a fluorescent histone acetyltransferase assay to probe the substrate specificity of human p300/CBP-associated factor. Anal. Biochem., 287, 319-328 (2000). (Pubitemid 32006243)
27. Yamagiwa, Y., Ohashi, K., Sakamota, Y., Hirakawa, S., Kamikawa, T., and Kubo, I., Syntheses of anacardic acids and ginkgoic acid. Tetrahedron, 43, 3387-3394 (1987).
28. Yashiro, M., Murahashi, K., Matsuoka, T., Tanaka, H., Osaka, H., Koyama, T., Ohira, M., and Chung, K. H., Tranilast (N-3,4-dimethoxycinnamyl anthranilic acid: A novel inhibitor of invasion-stimulating interaction between gastric cancer cells as orthotopic fibroblasts. Anticancer Res., 23, 3899-3904 (2003). (Pubitemid 37474340)
29. Wolffe, A. P. and Matzke, M. A., Epigenetics: regulation through repression. Science, 286, 481-486 (1999).